Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia

Next Previous
X
Search
Trial Profile

A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Patiromer (Primary)
  • Indications Hyperkalaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms OPAL-HK
  • Sponsors Relypsa

    • Most Recent Events

    • 01 Jul 2023 Results of post hoc pooled analysis (n=578) assessing the effect of patiromer on sP in patients with CKD, hyperkalemia, and hyperphosphatemia published in the American Journal of Kidney Diseases
    • 11 Apr 2018 According to the Relypsa media release, findings from pooled analysis from this and other two trials (AMETHYST-DN and TOURMALINE) will be presented in a poster session at the National Kidney Foundation's (NKF) 2018 Spring Clinical Meetings (SCM18).
    • 11 Apr 2018 Results from pooled analysis of this and other two trials (TOURMALINE and AMETHYST-DN) presented in the Relypsa media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top